Patient demographics
. | . | . | . | . | . | . | CBC at sampling . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y . | Sex . | Severity . | Initial treatment . | Duration of follow-up . | Response to Tx . | Hgb, g/dL . | ANC/μL . | Plts/μL . | Tx at sampling . | Transfusion status . | ||
| 1 | 36 | F | SAA | ATG/CsA/MMF | 3 y | CR | 12 | 2000 | 130 000 | None | No | ||
| 2 | 10 | M | SAA | None | New patient | N/A | 9 | 450 | 18 000 | None | N/A | ||
| 3 | 17 | M | SAA | ATG/CsA | 5 mo | PR | 8.5 | 500 | 4 000 | CsA | Plts | ||
| 4 | 58 | M | MAA | None | New patient | N/A | 8.5 | 1200 | 50 000 | None | RBCs | ||
| 5 | 27 | M | SAA | ATG/CsA | 1 y | PR | 9 | 700 | 28 000 | None | No | ||
| 6 | 35 | F | SAA | ATG/CsA | 8 mo | Nonresponder | 8.3 | 450 | 20 000 | None | RBCs and Plts | ||
| 7 | 15 | F | SAA | None | New patient | N/A | 8.8 | 350 | 10 000 | None | No | ||
| 8 | 38 | M | SAA | ATG/CsA | 8 y | PR | 10 | 1500 | 30 000 | None | No | ||
| 9 | 42 | M | SAA | ATG/CsA | 2 y | Relapsed | 8 | 450 | 5 000 | None | RBCs and Plts | ||
| 10 | 25 | M | SAA | ATG/CsA | 1 y | Relapsed | 8.2 | 700 | 25 000 | CsA | RBCs | ||
| 11 | 58 | F | SAA | ATG/CsA | 1 y | CR | 13.4 | 3500 | 106 000 | None | No | ||
| 12 | 43 | M | SAA | ATG/CsA | 2 y | Relapsed | 8 | 550 | 15 000 | None | No | ||
| 13 | 72 | F | SAA | ATG/CsA | 5 y | Relapsed | 9 | 700 | 20 000 | CsA | No | ||
| 14 | 79 | M | SAA | ATG/CsA | 3 y | CR | 12.5 | 2500 | 160 000 | None | No | ||
| 15 | 34 | F | SAA | ATG/CsA | 15 y | CR | 13.9 | 3500 | 120 000 | None | No | ||
| 16 | 63 | M | SAA | ATG/CsA | 2 y | Relapsed | 9 | 1500 | 16 000 | None | No | ||
| 17 | 40 | M | SAA | ATG/CsA | 5 y | Relapsed | 8 | 560 | 13 000 | CsA | Plts | ||
| 18 | 72 | M | SAA | ATG/CsA/G-CSF | 8 mo | Nonresponder | 8.4 | 900 | 15 000 | CsA | RBCs and Plts | ||
| 19 | 20 | F | SAA | ATG/CsA | 1 y | Nonresponder | 8.3 | 900 | 10 000 | None | RBCs and Plts | ||
| 20 | 67 | F | SAA | ATG/CsA | 2 y | Relapsed | 7.5 | 850 | 20 000 | None | RBCs | ||
| 21 | 23 | F | SAA | ATG/CsA | 1 y | CR | 12.8 | 2600 | 283 000 | None | No | ||
| 22 | 33 | F | SAA | ATG/CsA | 1 y | Nonresponder | 7.1 | 400 | 14 000 | CsA | RBCs | ||
| 23 | 63 | F | SAA | ATG/CsA | 3 y | PR | 10 | 815 | 58 000 | None | No | ||
| 24 | 35 | F | SAA | ATG/CsA | 2 y | CR | 10 | 2000 | 155 000 | None | No | ||
| 25 | 57 | F | SAA | ATG/CsA | 1 y | CR | 12 | 2350 | 125 000 | None | No | ||
| 26 | 25 | F | SAA | ATG/CsA | 3 y | CR | 13.5 | 3000 | 128 000 | None | No | ||
| 27 | 48 | M | SAA | ATG/CsA | 4 y | CR | 12 | 1950 | 155 000 | None | No | ||
| 28 | 20 | F | SAA | ATG/CsA | 1 y | PR | 9.5 | 800 | 45 000 | None | No | ||
. | . | . | . | . | . | . | CBC at sampling . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y . | Sex . | Severity . | Initial treatment . | Duration of follow-up . | Response to Tx . | Hgb, g/dL . | ANC/μL . | Plts/μL . | Tx at sampling . | Transfusion status . | ||
| 1 | 36 | F | SAA | ATG/CsA/MMF | 3 y | CR | 12 | 2000 | 130 000 | None | No | ||
| 2 | 10 | M | SAA | None | New patient | N/A | 9 | 450 | 18 000 | None | N/A | ||
| 3 | 17 | M | SAA | ATG/CsA | 5 mo | PR | 8.5 | 500 | 4 000 | CsA | Plts | ||
| 4 | 58 | M | MAA | None | New patient | N/A | 8.5 | 1200 | 50 000 | None | RBCs | ||
| 5 | 27 | M | SAA | ATG/CsA | 1 y | PR | 9 | 700 | 28 000 | None | No | ||
| 6 | 35 | F | SAA | ATG/CsA | 8 mo | Nonresponder | 8.3 | 450 | 20 000 | None | RBCs and Plts | ||
| 7 | 15 | F | SAA | None | New patient | N/A | 8.8 | 350 | 10 000 | None | No | ||
| 8 | 38 | M | SAA | ATG/CsA | 8 y | PR | 10 | 1500 | 30 000 | None | No | ||
| 9 | 42 | M | SAA | ATG/CsA | 2 y | Relapsed | 8 | 450 | 5 000 | None | RBCs and Plts | ||
| 10 | 25 | M | SAA | ATG/CsA | 1 y | Relapsed | 8.2 | 700 | 25 000 | CsA | RBCs | ||
| 11 | 58 | F | SAA | ATG/CsA | 1 y | CR | 13.4 | 3500 | 106 000 | None | No | ||
| 12 | 43 | M | SAA | ATG/CsA | 2 y | Relapsed | 8 | 550 | 15 000 | None | No | ||
| 13 | 72 | F | SAA | ATG/CsA | 5 y | Relapsed | 9 | 700 | 20 000 | CsA | No | ||
| 14 | 79 | M | SAA | ATG/CsA | 3 y | CR | 12.5 | 2500 | 160 000 | None | No | ||
| 15 | 34 | F | SAA | ATG/CsA | 15 y | CR | 13.9 | 3500 | 120 000 | None | No | ||
| 16 | 63 | M | SAA | ATG/CsA | 2 y | Relapsed | 9 | 1500 | 16 000 | None | No | ||
| 17 | 40 | M | SAA | ATG/CsA | 5 y | Relapsed | 8 | 560 | 13 000 | CsA | Plts | ||
| 18 | 72 | M | SAA | ATG/CsA/G-CSF | 8 mo | Nonresponder | 8.4 | 900 | 15 000 | CsA | RBCs and Plts | ||
| 19 | 20 | F | SAA | ATG/CsA | 1 y | Nonresponder | 8.3 | 900 | 10 000 | None | RBCs and Plts | ||
| 20 | 67 | F | SAA | ATG/CsA | 2 y | Relapsed | 7.5 | 850 | 20 000 | None | RBCs | ||
| 21 | 23 | F | SAA | ATG/CsA | 1 y | CR | 12.8 | 2600 | 283 000 | None | No | ||
| 22 | 33 | F | SAA | ATG/CsA | 1 y | Nonresponder | 7.1 | 400 | 14 000 | CsA | RBCs | ||
| 23 | 63 | F | SAA | ATG/CsA | 3 y | PR | 10 | 815 | 58 000 | None | No | ||
| 24 | 35 | F | SAA | ATG/CsA | 2 y | CR | 10 | 2000 | 155 000 | None | No | ||
| 25 | 57 | F | SAA | ATG/CsA | 1 y | CR | 12 | 2350 | 125 000 | None | No | ||
| 26 | 25 | F | SAA | ATG/CsA | 3 y | CR | 13.5 | 3000 | 128 000 | None | No | ||
| 27 | 48 | M | SAA | ATG/CsA | 4 y | CR | 12 | 1950 | 155 000 | None | No | ||
| 28 | 20 | F | SAA | ATG/CsA | 1 y | PR | 9.5 | 800 | 45 000 | None | No | ||
Conversion factors to render conventional units in SI units are as follows: for Hgb in g/L, × 10; for ANCs in × 109/L, × 106; for Plts in × 109/L, × 106.
CBC indicates complete blood count; Tx, treatment; Hgb, hemoglobin; ANC, absolute neutrophil count; Plts, platelets; F, female; SAA, severe aplastic anemia; ATG/CsA, antithymocyte globulin and cyclosporine; MMF, mycophenolate mofetil; CR, complete remission; M, male; N/A, not available; PR, partial remission; MAA, moderate aplastic anemia; and RBCs, packed red cells.